576 related articles for article (PubMed ID: 25239608)
1. Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.
Garner AP; Gozgit JM; Anjum R; Vodala S; Schrock A; Zhou T; Serrano C; Eilers G; Zhu M; Ketzer J; Wardwell S; Ning Y; Song Y; Kohlmann A; Wang F; Clackson T; Heinrich MC; Fletcher JA; Bauer S; Rivera VM
Clin Cancer Res; 2014 Nov; 20(22):5745-5755. PubMed ID: 25239608
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate.
Prenen H; Cools J; Mentens N; Folens C; Sciot R; Schöffski P; Van Oosterom A; Marynen P; Debiec-Rychter M
Clin Cancer Res; 2006 Apr; 12(8):2622-7. PubMed ID: 16638875
[TBL] [Abstract][Full Text] [Related]
3. Selecting tyrosine kinase inhibitors for gastrointestinal stromal tumor with secondary KIT activation-loop domain mutations.
Hsueh YS; Lin CL; Chiang NJ; Yen CC; Li CF; Shan YS; Ko CH; Shih NY; Wang LM; Chen TS; Chen LT
PLoS One; 2013; 8(6):e65762. PubMed ID: 23840364
[TBL] [Abstract][Full Text] [Related]
4. Spectrum of activity of dasatinib against mutant KIT kinases associated with drug-sensitive and drug-resistant gastrointestinal stromal tumors.
Zeng C; Zhu L; Jia X; Pang Y; Li Z; Lu X; Xie F; Duan L; Wang Y
Gastric Cancer; 2020 Sep; 23(5):837-847. PubMed ID: 32291709
[TBL] [Abstract][Full Text] [Related]
5. Gastrointestinal stromal tumors.
Antonescu C
Curr Top Microbiol Immunol; 2012; 355():41-57. PubMed ID: 22015552
[TBL] [Abstract][Full Text] [Related]
6. Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor.
Heinrich MC; Maki RG; Corless CL; Antonescu CR; Harlow A; Griffith D; Town A; McKinley A; Ou WB; Fletcher JA; Fletcher CD; Huang X; Cohen DP; Baum CM; Demetri GD
J Clin Oncol; 2008 Nov; 26(33):5352-9. PubMed ID: 18955458
[TBL] [Abstract][Full Text] [Related]
7. Flumatinib, a selective inhibitor of BCR-ABL/PDGFR/KIT, effectively overcomes drug resistance of certain KIT mutants.
Zhao J; Quan H; Xu Y; Kong X; Jin L; Lou L
Cancer Sci; 2014 Jan; 105(1):117-25. PubMed ID: 24205792
[TBL] [Abstract][Full Text] [Related]
8. Resistance to c-KIT kinase inhibitors conferred by V654A mutation.
Roberts KG; Odell AF; Byrnes EM; Baleato RM; Griffith R; Lyons AB; Ashman LK
Mol Cancer Ther; 2007 Mar; 6(3):1159-66. PubMed ID: 17363509
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological Inhibition of KIT Activates MET Signaling in Gastrointestinal Stromal Tumors.
Cohen NA; Zeng S; Seifert AM; Kim TS; Sorenson EC; Greer JB; Beckman MJ; Santamaria-Barria JA; Crawley MH; Green BL; Rossi F; Besmer P; Antonescu CR; DeMatteo RP
Cancer Res; 2015 May; 75(10):2061-70. PubMed ID: 25836719
[TBL] [Abstract][Full Text] [Related]
10. Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours.
Serrano C; Mariño-Enríquez A; Tao DL; Ketzer J; Eilers G; Zhu M; Yu C; Mannan AM; Rubin BP; Demetri GD; Raut CP; Presnell A; McKinley A; Heinrich MC; Czaplinski JT; Sicinska E; Bauer S; George S; Fletcher JA
Br J Cancer; 2019 Mar; 120(6):612-620. PubMed ID: 30792533
[TBL] [Abstract][Full Text] [Related]
11. A novel tyrosine kinase switch is a mechanism of imatinib resistance in gastrointestinal stromal tumors.
Mahadevan D; Cooke L; Riley C; Swart R; Simons B; Della Croce K; Wisner L; Iorio M; Shakalya K; Garewal H; Nagle R; Bearss D
Oncogene; 2007 Jun; 26(27):3909-19. PubMed ID: 17325667
[TBL] [Abstract][Full Text] [Related]
12. Mechanisms of sunitinib resistance in gastrointestinal stromal tumors harboring KITAY502-3ins mutation: an in vitro mutagenesis screen for drug resistance.
Guo T; Hajdu M; Agaram NP; Shinoda H; Veach D; Clarkson BD; Maki RG; Singer S; Dematteo RP; Besmer P; Antonescu CR
Clin Cancer Res; 2009 Nov; 15(22):6862-70. PubMed ID: 19861442
[TBL] [Abstract][Full Text] [Related]
13. [The importance of mutational status in prognosis and therapy of GIST].
Comandone A; Boglione A
Recenti Prog Med; 2015 Jan; 106(1):17-22. PubMed ID: 25621775
[TBL] [Abstract][Full Text] [Related]
14. Sorafenib inhibits many kinase mutations associated with drug-resistant gastrointestinal stromal tumors.
Heinrich MC; Marino-Enriquez A; Presnell A; Donsky RS; Griffith DJ; McKinley A; Patterson J; Taguchi T; Liang CW; Fletcher JA
Mol Cancer Ther; 2012 Aug; 11(8):1770-80. PubMed ID: 22665524
[TBL] [Abstract][Full Text] [Related]
15. Increased KIT inhibition enhances therapeutic efficacy in gastrointestinal stromal tumor.
Kim TS; Cavnar MJ; Cohen NA; Sorenson EC; Greer JB; Seifert AM; Crawley MH; Green BL; Popow R; Pillarsetty N; Veach DR; Ku AT; Rossi F; Besmer P; Antonescu CR; Zeng S; Dematteo RP
Clin Cancer Res; 2014 May; 20(9):2350-62. PubMed ID: 24583793
[TBL] [Abstract][Full Text] [Related]
16. Clinical efficacy of second-generation tyrosine kinase inhibitors in imatinib-resistant gastrointestinal stromal tumors: a meta-analysis of recent clinical trials.
Wu L; Zhang Z; Yao H; Liu K; Wen Y; Xiong L
Drug Des Devel Ther; 2014; 8():2061-7. PubMed ID: 25378911
[TBL] [Abstract][Full Text] [Related]
17. C-kit, GIST, and imatinib.
Siehl J; Thiel E
Recent Results Cancer Res; 2007; 176():145-51. PubMed ID: 17607922
[TBL] [Abstract][Full Text] [Related]
18. The Novel HSP90 inhibitor, IPI-493, is highly effective in human gastrostrointestinal stromal tumor xenografts carrying heterogeneous KIT mutations.
Floris G; Sciot R; Wozniak A; Van Looy T; Wellens J; Faa G; Normant E; Debiec-Rychter M; Schöffski P
Clin Cancer Res; 2011 Sep; 17(17):5604-14. PubMed ID: 21737509
[TBL] [Abstract][Full Text] [Related]
19. Combination of Imatinib Mesylate and AKT Inhibitor Provides Synergistic Effects in Preclinical Study of Gastrointestinal Stromal Tumor.
Zook P; Pathak HB; Belinsky MG; Gersz L; Devarajan K; Zhou Y; Godwin AK; von Mehren M; Rink L
Clin Cancer Res; 2017 Jan; 23(1):171-180. PubMed ID: 27370604
[TBL] [Abstract][Full Text] [Related]
20. KIT mutations in GIST.
Fletcher JA; Rubin BP
Curr Opin Genet Dev; 2007 Feb; 17(1):3-7. PubMed ID: 17208434
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]